English 
Chinese 
Russian 
French MSC Therapy for Chronic Kidney Disease: What the 2025 Evidence Shows
A 2025 meta-analysis of 52 studies, real-world Taiwan data, and Mayo Clinic intraarterial delivery results — what nephrologists need to know about MSCs and CKD.
14Oct
23Sep
MSC Therapy for Pulmonary Fibrosis: 2026 Preclinical and Clinical Evidence Review
A medical review of MSC-based and MSC-derived EV therapies for idiopathic pulmonary fibrosis, covering meta-analysis data, immune-cloaked cell engineering, nebulized exosome delivery, gut-lung axis mechanisms, and active clinical trials.
07Sep
MSC Therapy for Ischemic Stroke: What a 2026 Umbrella Review and Network Meta-Analysis of 1,006 Patients Reveal
The 2026 evidence base for mesenchymal stem cell therapy in ischemic stroke includes a 26-study umbrella review and an 18-RCT network meta-analysis of 1,006 patients. MSCs were the only cell type to significantly reduce mortality. This medical review synthesizes the latest clinical data, mechanisms, active trials, and translational barriers.
08Jun
MSC Therapy for Graft-versus-Host Disease: What 15 RCTs and a Biomarker-Guided Trial Tell Us
A 2026 meta-analysis of 15 RCTs shows MSCs cut acute GvHD incidence by 53% and chronic GvHD by 50%. A biomarker-guided trial identifies which transplant patients benefit most — and a cell-free exosome approach may be next.
29May
MSC Immunomodulation in Autoimmune Disease: Mechanisms, Clinical Evidence, and Therapeutic Windows
A technical deep dive into MSC immunomodulation for autoimmune disease: Treg induction, macrophage polarization, and clinical evidence from the SMART-MS trial.